C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation

August 14, 2024

https://www.globenewswire.com/news-release/2024/08/14/2929923/0/en/C4-Therapeutics-Announces-European-Society-for-Medical-Oncology-ESMO-Changed-the-Previously-Accepted-CFT1946-Preliminary-Phase-1-Abstract-to-a-Proffered-Paper-Presentation.html

WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the ESMO Congress decided to move C4T’s previously accepted preliminary monotherapy Phase 1 abstract for CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, to an oral presentation. This oral presentation session at the ESMO Congress 2024 is scheduled for Friday, September 13, 2024, at 4:00 pm to 5:30 pm CEST. Additionally, C4T announced it will host an investor webcast on Friday, September 13, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.